Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PPI Marketers Target Patients Leaving COX-2s For NSAIDs

This article was originally published in The Tan Sheet

Executive Summary

Proton pump inhibitor marketers are poised to benefit from potential cardiovascular risk warnings for COX-2 inhibitors that could increase the migration of arthritis patients to traditional NSAIDs

You may also be interested in...

“Black Box” Gives Black Eye To Prospects For COX-2 Ads Returning

While an FDA advisory committee voted strongly in favor of allowing continued marketing of Celebrex (celecoxib), the panel's recommendations for warnings diminish the prospects of renewed DTC marketing

Prevacid NapraPAC Scripts Suggest PPI/NSAID Combos May Thrive Post-Vioxx

TAP's Prevacid NapraPAC is among the early winners in the arthritis market following the withdrawal of Merck's Vioxx, IMS Health data suggest

AstraZeneca Nexium Cleared For Lowering Risk Of NSAID-Related Ulcers

A supplemental approval for Nexium will allow AstraZeneca to position the proton pump inhibitor as an alternative to switching patients to a COX-2 to reduce the risk of gastric ulcers associated with continuous NSAID therapy

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts